Purification and Characterization of 1-O-Acylceramide Synthase, a Novel Phospholipase A2 with Transacylase Activity*

Akira Abe and James A. ShaymanDagger

From the Division of Nephrology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

A novel pathway for ceramide metabolism, 1-O-acylceramide formation, was previously reported (Abe, A., Shayman, J. A., and Radin, N. S. (1996) J. Biol. Chem. 271, 14383-14389). In this pathway a fatty acid in the sn-2 position of phosphatidylethanolamine or phosphatidylcholine is transferred to the 1-hydroxyl position of ceramide. An enzyme that catalyzes the esterification of N-acetylsphingosine was purified from the postmitochondrial supernatant of calf brain through consecutive steps, including ammonium sulfate fractionation, DEAE-Sephacel, phenyl-Sepharose, S-Sepharose, Sephadex G-75, concanavalin A-agarose, and heparin-Sepharose chromatography. The molecular mass of the enzyme was determined to be 40 kDa by gel filtration on Sephadex G-75. The enzyme bound to concanavalin A-agarose column was eluted with the buffer containing 500 mM alpha -methyl-D-mannopyranoside. Further purification by heparin-Sepharose chromatography resulted in separation of two peaks of enzyme activity. Coincidence between the transacylase activity and a stained protein of a molecular mass of 40 kDa was observed, as determined by SDS-polyacrylamide gel electrophoresis and recovery after separation over an acidic native gel. The second peak of activity from the heparin-Sepharose chromatography represented a purification of 193,000-fold. These results are consistent with the enzyme being a glycoprotein of a molecular mass of about 40 kDa with a single polypeptide chain. The purified enzyme had a pH optimum at pH 4.5. The divalent cations Ca2+ and Mg2+ enhanced but were not essential for the transacylase activity. Neither activation nor inactivation of the enzyme activity was observed in the presence of 2 mM ATP or 2 mM dithiothreitol. Preincubation of the enzyme with 1 mM N-ethylmaleimide, 1 mM phenylmethylsulfonyl fluoride, or 3.1 µM bromoenol lactone, a potent inhibitor of cytosolic Ca2+-independent phospholipase A2, had no significant effect on the enzyme activity. The enzyme activity was completely abolished in the presence of greater than 773 µM Triton X-100. Partial inhibition of the enzyme activity was observed in the presence of 10-100 µg/ml heparin. In the absence of N-acetylsphingosine, the enzyme acted as a phospholipase A2. These results strongly suggest that 1-O-acylceramide synthase is both a transacylase and a novel phospholipase A2.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Recently ceramide has been identified as a candidate lipid mediator regulating cell proliferation, growth, differentiation, development, and apoptosis (1, 2). In many studies, proof of concept for a biological role of ceramide has relied on the use of N-acetylsphingosine (NAS),1 a truncated and membrane-permeable homologue of endogenous ceramides. Reliance on NAS is problematic since this compound is subject to metabolism when exogenously applied to cultured cells. We observed that MDCK cells and NIH 3T3 cells actively metabolized and converted NAS to other sphingolipids and resulted in a considerable increase in levels of sphingosine, natural (long chain) ceramide, and glucosylceramide (3-5).

Previously reported work on the metabolism of NAS in MDCK cell homogenates revealed the formation of a unique, alkali-labile lipid, 1-O-acylceramide (5). An enzyme activity that catalyzed esterification of a hydroxyl group at C1 position of NAS was described. The enzyme displayed an acidic pH optimum and was mainly recovered in a soluble fraction after centrifugation at 100,000 × g. In the presence of NAS and using liposomes consisting of phosphatidylcholine, [2-14C]arachidonylphosphatidylethanolamine and sulfatide, the enzyme catalyzed both the transacylation of NAS and the release of arachidonic acid from phosphatidylethanolamine. In the absence of NAS, the release of arachidonic acid was still observed. The enzyme predominantly catalyzes the deacylation or transacylation of both phosphatidylethanolamine and phosphatidylcholine. Additionally, Ca2+ was not required for the enzyme activity. This enzyme appeared to be a novel Ca2+-independent PLA2. In the present paper, we report the purification and characterization of this novel acid phospholipase A2 with transacylase activity from calf brain.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials

The reagents and their sources were L-alpha -1-acyl-2-[1-14C]arachidonoylphosphatidylethanolamine (53 mCi/mmol) from Amersham Pharmacia Biotech; [3H]acetic anhydride (50-100 mCi/mmol) from American Radiolabeled Chemicals; Ecolume scintillation fluid from ICN; N-ethylmaleimide, Triton X-100, phosphatidylethanolamine (PE) from bovine brain, dicetylphosphate, D-erythro-sphingosine, heparin, phenylmethylsulfonyl fluoride (PMSF), alpha -methyl-D-mannopyranoside, and S-Sepharose from Sigma; dioleoylphosphatidylcholine (DOPC) from Avanti; DL-dithiothreitol (DTT) and nonadecyltetraenyl trifluoromethyl ketone (AACOCF3) from Calbiochem; (E)-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-(2H)-pyran-2-one (BEL) from Cayman Chemical. N-[3H]Acetylsphingosine ([3H]NAS) was prepared by the method of Gaver and Sweeley (6). High performance thin layer chromatography silica gel plates, 10 × 20 cm, were purchased from Merck. DEAE-Sephacel, phenyl-Sepharose CL-4B, Sephadex G-75, and heparin-Sepharose were from Amersham. Concanavalin A (Con A)-agarose was from Seikagaku Inc., Japan. Protein molecular mass standards used for Sephadex G-75 gel filtration and SDS-polyacrylamide gel electrophoresis included the following: bovine serum albumin, 68 kDa (Amersham); ovalbumin, 43 kDa (Sigma); carbonic anhydrase, 29 kDa (Amersham); and cytochrome c, 12.5 kDa (Amersham).

Polyacrylamide Gel Electrophoresis

Polyacrylamide gel electrophoresis in the absence of SDS was performed by the modified method of Reisfeld et al. (7) on 10% acrylamide gels at pH 4.3. Polyacrylamide gel electrophoresis in the presence of SDS was performed by the method of Laemmli and Favre (8) on 12% acrylamide gel. The protein bands were stained with Coomassie Brilliant Blue R-250 or using a silver staining kit (Bio-Rad). The protein content was determined by the bicinchroninic acid protein assay (Pierce) with bovine serum albumin as a standard. The solution with a low concentration of protein was concentrated by the deoxychorate-trichloroacetic acid precipitation method (9) and then assayed.

When the transacylase activity was extracted from a polyacrylamide gel, two gels were loaded with the partially purified enzyme (Step 7, see below) in 0.02% methyl green plus 10% glycerol. Electrophoresis was performed in a cold room. One gel was sliced into 2-mm segments. Each gel was minced by a glass homogenizer with 650 µl of 50 mM sodium citrate (pH 4.5) and vortexed overnight at 4 °C. The samples were centrifuged for 10 min at 2,000 × g to remove the gel particles. The transacylase activity was measured for each sample using 400 µl of supernatant. The other gel was equilibrated for 2 h against 2.3% SDS, 5% 2-mercaptoethanol, 10% glycerol, 62.5 mM Tris-HCl (pH 6.8) and then electrophoresed to a slab polyacrylamide gel (12% separating gel) in the presence of SDS.

Enzyme Assay

The assay conditions are described in the figure and table legends. In general, liposomes consisting of DOPC (70 mol%), PE (30 mol%), and dicetylphosphate (10 mol%) were used as acyl group donors. Constituent lipids in chloroform were mixed and dried under a stream of nitrogen. Fifty mM sodium citrate (pH 4.5) was added to the dried lipids at a volume 1 ml/1.28 µmol of lipid phosphorus. The lipids were dispersed into the buffer for 8 min in an ice water bath using a probe sonicator. The donor liposomes (64 nmol of phospholipid) were incubated with 5 nmol of [3H]NAS (10,000 cpm), 5 µg of bovine serum albumin and the transacylase activity at 37 °C in a total volume of 500 µl of 38-40 mM sodium citrate (pH 4.5). The reaction was terminated by adding 3 ml of chloroform/methanol (2/1). The activity was determined as described in the previous paper (5). In the assay using nonradioactive NAS, the lipids were extracted and chromatographied as in the use of radioactive NAS. The activity was determined by image scan analysis of O-acyl-NAS band obtained by charring.

Purification of Transacylase from Calf Brain

Postmitochondrial Supernatant (Step 1)-- Fresh calf brains were stored at -80 °C as thin blocks after removal of pia mater. Frozen brains (600 g) were partly allowed to thaw in the cold room overnight and then cut in small pieces, after which all manipulations were performed at 4 °C. A 30% homogenate in 10 mM Tris-HCl (pH 7.4 at room temperature), 1 mM EDTA, 0.5 mM PMSF (buffer A) was prepared by a Polytron for 1 min at 20,000 rpm. The mixture was centrifuged at 14,000 × g for 30 min. The pellet was reextracted as described above.

Ammonium Sulfate Precipitation (Step 2)-- Ammonium sulfate was added to the postmitochondrial supernatant to 20% saturation (10.6 g/100 ml). After stirring for 1 h, the precipitate was removed by centrifugation at 14,000 × g for 30 min. The supernatant was adjusted to 70% saturation with ammonium sulfate (31.2 g/100 ml) to precipitate the enzyme. After standing overnight, the clear supernatant above the precipitate was siphoned off. The precipitate was collected by centrifugation at 10,000 × g for 30 min, dissolved in 60 ml of buffer A, and dialyzed for 2 days against 5 times 4 liters of 25 mM Tris-HCl (pH 7.4, at room temperature), 1 mM EDTA (buffer B). The protein was adjusted to less than 20 mg/ml with buffer B and centrifuged at 100,000 × g for 1 h.

DEAE-Sephacel Chromatography (Step 3)-- The supernatant was applied to a column (5 × 22 cm) of DEAE-Sephacel preequilibrated with buffer B at a flow rate of 100 ml/h. Unbound protein was eluted with 2 liters of buffer B. The enzyme activity was recovered in the unbound fraction.

Phenyl-Sepharose Chromatography (Step 4)-- The unbound fraction was adjusted to 3 M NaCl and then applied to a column (2.5 × 20 cm) of phenyl-Sepharose preequilibrated with buffer B containing 3 M NaCl (buffer C) at a flow rate of 80 ml/h. Unbound material was eluted with 1000 ml of buffer C. Additionally the column was rinsed by 450 ml of buffer B containing 1.5 M NaCl (buffer C') and then by 400 ml of buffer B containing 0.15 M NaCl (buffer D). A small portion of the enzyme activity was released from the column during rinsing by buffer D. Most enzyme activity was eluted by 400 ml of buffer D containing 50% (w/v) ethylene glycol (buffer E) and kept at -80 °C.

The same procedure, steps 1-4, was separately carried out 4 times. Then each fraction kept at -80 °C after the phenyl-Sepharose chromatography step was combined and dialyzed against 10 mM sodium phosphate (pH 6.0), 1 mM EDTA (buffer F).

S-Sepharose Chromatography (Step 5)-- The dialysate was applied to a column (1.4 × 20 cm) of S-Sepharose preequilibrated with buffer F at a flow rate of 40 ml/h. Unbound protein was eluted by buffer F. The bound protein was eluted by a 480-ml linear gradient of NaCl from 0-0.3 M NaCl in buffer F. The enzyme activity was found in fractions between 60 and 130 mM NaCl as two peaks. Each peak was separately collected and named "S-Sepharose fast" and "S-Sepharose slow" by following the order of elution.

Sephadex G-75 Chromatography (Step 6)-- Both fractions, S-Sepharose fast and S-Sepharose slow, were concentrated by Centriprep-10 (Amicon) and then applied separately to a column (2.6 × 90 cm) of Sephadex G-75 preequilibrated with 0.15 M NaCl, 25 mM Tris-HCl (pH 7.4), 1 mM EDTA (buffer D) at a flow rate of 40 ml/h. Protein was eluted with buffer D. For S-Sepharose slow, a peak of the enzyme activity appeared at Ve/Vo = 1.41. For S-Sepharose fast, two small peaks of the enzyme activity were observed at Ve/Vo = 1.12 and 1.41. The active fractions obtained from S-Sepharose slow were collected and used for further purification.

Concanavalin A-Agarose Chromatography (Step 7)-- The fraction obtained in Step 6 was adjusted to 1 mM CaCl2 and 1 mM MnCl2 and applied to a column (0.85 × 1.8 cm) of Con A-agarose preequilibrated in 500 mM NaCl, 25 mM Tris-HCl (pH 7.4), 1 mM CaCl2, and 1 mM MnCl2 (buffer G) at a flow rate 1.5 ml/h. Unbound protein was eluted by 10 ml of buffer G. The column was rinsed by buffer G including 10 mM alpha -methyl-D-mannopyranoside. During the rinse, a small portion of the enzyme activity was released from the column. Most enzyme activity was eluted by 10 ml of buffer G including 500 mM alpha -methyl-D-mannopyranoside (buffer H) and possessed a very high specific activity in the transacylase assay. The active fraction eluted with buffer H was collected, adjusted to 77.3 µM of Triton X-100, and then dialyzed against 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 77.3 µM (w/v) Triton X-100 (buffer I).

Heparin-Sepharose Chromatography (Step 8)-- The dialysate was applied to a column of heparin-Sepharose (HiTrap heparin, 1 ml; Amersham) preequilibrated in buffer I at a flow rate of 5 ml/h. Unbound protein was eluted by 15 ml of buffer I. Then the column was rinsed by 15 ml of buffer B containing 77.3 µM Triton X-100 (buffer B'). The bound protein was eluted by a 60-ml linear gradient of NaCl from 0 to 0.15 M in buffer B'.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Purification of Transacylase from Calf Brain

Table I summarizes the various steps of the protocol developed for transacylase purification. An eight-step procedure was employed, and the transacylase activity was monitored by the acylation of NAS throughout the purification.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Purification of transacylase from calf brain

In the present study, calf brain was chosen as a starting material. The post-mitochondrial supernatant was precipitated by 20-70% ammonium sulfate. After dialyzing the suspension of the precipitates, the 100,000 × g supernatant of the dialysate was applied to the DEAE-Sephacel column, and most of the enzyme activity was recovered in the unbound fraction. The recovery rebounded after the DEAE-Sephacel elution. This step gave rise to about 19-fold purification. The unbound fraction was adjusted to 3 M NaCl and applied to the phenyl-Sepharose column. The enzyme activity was recovered by the buffer containing 50% ethylene glycol (Fig. 1). This step gave rise to an additional 7.6-fold purification.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 1.   Phenyl-Sepharose CL-4B column chromatography. The active fraction obtained from the DEAE-Sephacel chromatography step was adjusted to 3 M NaCl and applied to the phenyl-Sepharose CL-4B column. Arrows at Buffer D and Buffer E indicate the point at which elution buffers were changed to 0.15 M NaCl, 25 mM Tris-HCl (pH 7.4), 1 mM EDTA, and 50% ethylene glycol, 0.15 M NaCl, 25 mM Tris-HCl (pH 7.4), 1 mM EDTA, respectively. The column was eluted as described under "Experimental Procedures." 6.6 ml fractions and 5.5 ml fractions were collected in tubes number 1-57 and 76-120, respectively. Thirty-µl aliquots were assayed for the transacylase activity (black-square). Protein was measured as absorbance at 280 nm (open circle ).

In the next S-Sepharose chromatography, the enzyme activity was eluted in fractions between 60 and 130 mM NaCl as two peaks (Fig. 2). There was no enrichment in the purification of the S-Sepharose fast fraction. On the other hand the S-Sepharose slow fraction was purified 4.1-fold.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2.   S-Sepharose column chromatography. The active fraction from the phenyl-Sepharose chromatography step (fractions 76-105) was dialyzed against 10 mM sodium phosphate (pH 6.0), 1 mM EDTA (buffer F). The dialysate was applied to the S-Sepharose column and eluted as described under "Experimental Procedures." Six-ml fractions were collected in tubes. Fifteen-µl aliquots were assayed for the transacylase activity (black-square). (open circle ) and (- - -) denote absorbance at 280 nm and NaCl concentration, respectively.

Before step 6 (Sephadex G-75 gel filtration), both S-Sepharose fast and S-Sepharose slow fractions were concentrated using Centriprep-10 without loss of enzyme activity. Only a small increase in purity was produced by gel filtration. For S-Sepharose slow, a peak of the enzyme activity appeared at Ve/Vo = 1.41 (Fig. 3B). On the other hand, for S-Sepharose fast two small peaks of the enzyme activity were observed at Ve/Vo = 1.12 and 1.41 (Fig. 3A). The values of Ve/Vo, 1.12 and 1.41, corresponded to molecular masses of 77.5 kDa and 38.6 kDa, respectively. The active fractions shown in the Fig. 3B were collected and used for further purification.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 3.   Sephadex G-75 column chromatography. Two active fractions obtained from the S-Sepharose column, fractions 17-27 (S-Sepharose fast) and fractions 28-37 (S-Sepharose slow), were concentrated by Centriprep-10 and then separately applied to the Sephadex G-75 column. Protein was eluted with 0.15 M NaCl, 25 mM Tris-HCl (pH 7.4), 1 mM EDTA. Six-ml fractions were collected. Thirty-µl aliquots were assayed for the transacylase activity (black-square). (open circle ) denotes absorbance at 280 nm. Panels A and B resulted from the fractions S-Sepharose fast and S-Sepharose slow, respectively.

Most proteins passed through the Con A agarose column (Fig. 4). Buffer containing 500 mM alpha -methyl-D-mannopyranoside was required to elute the enzyme (Fig. 4). This step gave rise to an additional 55-fold purification. Further recovery of the enzyme was accomplished by maintaining the column in buffer H overnight without elution and then rinsing with the same buffer. Because the protein concentration in the active fraction was extremely low, the protein solution was stabilized with 77.3 µM Triton X-100. At this stage, the purified transacylase was separated by acidic native gel electrophoresis. The extraction of gel slices and assay of transacylase activity corresponded to a protein of a molecular mass 40 kDa (Fig. 5).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 4.   Concanavalin A-agarose column chromatography. The active fractions 38-43 shown in the Fig. 5B were pooled, adjusted to 1 mM CaCl2 and 1 mM MnCl2, and applied to a concanavalin A column. The column was eluted as described under "Experimental Procedures." Arrows A and B indicate the point at which elution buffers were changed to 10 mM alpha -methyl-D-mannopyranoside (MeMan, buffer G) and 500 mM alpha -methyl-D-mannopyranoside (buffer H), respectively. 4-ml fractions were collected except fractions 21-42, where 1-ml fractions were collected. 10-µl aliquots were assayed for the transacylase activity (black-square). (open circle ) denotes absorbance at 280 nm.


View larger version (76K):
[in this window]
[in a new window]
 
Fig. 5.   Gel electrophoresis and recovery of 1-O-acylceramide synthase. Gel electrophoresis and the transacylase enzyme assay were carried out as described under "Experimental Procedures." The upper panel displays the two-dimensional gel electrophoresis pattern of the active fraction obtained from the concanavalin A-agarose column. The lower panel displays the enzyme activity profile by thin layer chromatography and charring observed in a parallel gel after separation in the first dimension. The location of the transacylase activity (Rf 0.19-0.35) in the native gel corresponded to the protein band with a molecular mass of 40 kDa as seen by separation in the second dimension. The first two lanes represent separated extracts from an assay performed in the presence of liposomes only and from a sample before native gel electrophoresis.

The active fraction obtained from the Con A column was applied to the heparin-Sepharose column and eluted by a linear gradient of 0-150 mM NaCl. No Con A and Con A fragments were contaminated in the sample after heparin-Sepharose chromatography. The enzyme activity appeared as two peaks between 20 and 50 mM NaCl (Fig. 6). In this single experiment the elution profile of the enzyme activity corresponded to that of protein of a molecular mass 40 kDa, estimated by SDS-PAGE. The lack of a protein band in lane 30 was due to the accidental loss of deoxycholate-trichloroacetic acid precipitate during aspiration. The highly purified enzyme found in the second peak was purified 193,000-fold. The protein appeared as a single band by SDS-PAGE and was used for further characterization of the enzyme. The yield from 10 calf brains (2,400 × g) was 4.5 µg with a specific activity of 25 µmol/min/mg of protein. The overall recovery of the activity was 1.6%. Transacylase activity was always accompanied with phospholipase A activity throughout the purification steps as determined by thin layer chromatography and charring (for example, Fig. 5).


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 6.   Heparin-Sepharose column chromatography. The active fractions obtained from the concanavalin A column (fractions 32-42) were pooled, adjusted to 77.3 µM Triton X-100, and dialyzed against 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 77.3 µM Triton X-100 (buffer I). The column was eluted as described under "Experimental Procedures." 3.42-ml fractions and 0.57-ml fractions were collected in tubes 1-10 and 11-70, respectively. Ten-µl aliquots were assayed for the transacylase activity (open circle ). (- - -) denotes the NaCl concentration. The upper panel shows SDS-PAGE of the heparin-Sepharose chromatography. Each sample (50 µl) was precipitated by the method of Bensadoun and Weinstein (9). The resultant precipitate was dissolved with 20 µl of 400 mM Tris, 1.5% SDS, 10% glycerol, 2% 2-mercaptoethanol, 0.005% bromphenol blue and applied to lanes numbered 2-32. The bands were visualized by silver stain. The indistinct bands, which are not proteins, at the area around molecular mass 43-68 kDa are an artifact produced by the addition of 2-mercaptoethanol to the samples.

Characterization of Transacylase

pH Optimum-- The purified transacylase was optimally active at pH 4.5 (Fig. 7). Unlike the homogenate obtained from MDCK cells, the purified enzyme still retained the activity at pH 5-6.5 (5). The enzyme activity was totally abolished at pH greater than 7.6. 


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 7.   pH dependence of transacylase activity. The reaction mixture consisted of citric acid-Na2HPO4 buffer (29), DOPC/PE/dicetylphosphate (7/3/1, 128 µM total phospholipid) liposomes, 10 µg/ml BSA, 10 µM [3H]NAS), and 6 ng/ml purified transacylase. The reaction was kept for 10 min at 37 °C.

Effect of Ca2+-- The enzyme activity was slightly inhibited in the presence of 5 mM EDTA. One and 10 mM Ca2+ enhanced the activity by 48 and 27%, respectively (Table II). A similar effect was observed in the presence of Mg2+, in which 1 and 10 mM Mg2+ enhanced the activity by 32% and 43%, respectively.

                              
View this table:
[in this window]
[in a new window]
 
Table II
The effect of inhibitors and activators on purified transacylase
The control incubation consisted of 40 mM sodium acetate (pH 4.5), 10 µM [3H]NAS, 10 µg/ml BSA, PC/PE/dicetylphosphate liposomes and 6 ng/ml enzyme. The enzyme activity of the control was 20 µmol/min/mg of protein. In the experiments with NEM, DTT, or PMSF, the enzyme was preincubated for 40 min at 0 °C with the compounds in Tris buffer at pH 7.4. In the experiment with BEL, the enzyme was preincubated for 6 min at 25 °C with 3.1 µM BEL. Values are mean ± S.D. for n = 3 except for ATP and NEM (n = 2).

Effect of Other Agents-- Nucleotides, in particular ATP, have been reported to stabilize and activate a cytosolic Ca2+-independent PLA2 (10, 11). The transacylase activity was slightly inhibited in the presence of 2 mM ATP (Table II). Neither the thiol compound, DTT, nor the thiol reagent, NEM, had significant effects on the enzyme activity (Table II). The transacylase activity was slightly inhibited by the pretreatment of the enzyme with 1 mM PMSF (Table II). Both BEL, a potent inhibitor of cytosolic Ca2+-independent PLA2 (iPLA2), and AACOCF3, a potent inhibitor of cytosolic PLA2 (cPLA2), slightly inhibited the enzyme activity (Table II and Fig. 8).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of AACOCF3 on transacylase activity. The reaction mixture contained 38.5 mM sodium citrate (pH 4.5), DOPC/PE/dicetylphosphate (7/3/1, 128 µM phospholipid) liposomes, 10 µg/ml BSA, 10 µM [3H]NAS, 6 ng/ml purified transacylase in the absence or presence of 28 µM AACOCF3. Incubation was carried out at 37 °C. Values represent the mean ± S.D. (n = 3).

In the last purification step, 77.3 µM Triton X-100 was used to stabilize the enzyme. Using the active fraction of Sephadex G-75 (from S-Sepharose slow), it was found that there was no significant difference in the enzyme activity between the fractions in the presence and in the absence of 77.3 µM Triton X-100 if the final concentration of Triton X-100 in the assay system was reduced less than 773 nM. However, the transacylase activity was strongly affected in the presence of higher concentrations of Triton X-100. The activity completely disappeared in the presence of greater than 773 µM Triton X-100 (Fig. 9).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 9.   Effect of Triton X-100 on transacylase activity. The reaction mixture contained 38.5 mM sodium citrate (pH 4.5), DOPC/PE/dicetylphosphate (7/3/1, 128 µM phospholipid) liposomes, 10 µg/ml BSA, 10 µM [3H]NAS, 3.07 µg/ml active fraction from the Sephadex G-75 column (Fig. 5B) in the absence or presence of Triton X-100. Incubation was for 10 min at 37 °C. Values represent the mean ± S.D. (n = 3).

In a preliminary test, it was found that the enzyme activity in the active fraction of Sephadex G-75 eluate (from S-Sepharose slow) was partially inhibited by 100 µg/ml heparin. As already shown in Fig. 6, the enzyme was bound to heparin-Sepharose resin. Fifty percent inhibition of the enzyme activity was observed in the presence of 10-100 µg/ml heparin (Table II).

Dual Enzyme Activity, Transacylase and Phospholipase A2-- As noted above, the transacylase was always accompanied with phospholipase A activity. To confirm the existence of both transacylase and phospholipase A activities, L-alpha -1-acyl-2-[1-14C]arachidonoyl-PE was employed as an acyl donor. The enzyme acted as not only a transacylase but also as a PLA2 in the presence of NAS and sn-2-radiolabeled PE (Fig. 10). On the other hand, the enzyme showed only PLA2 activity in the absence of NAS as an acceptor. Interestingly, the total activity of the transacylase and PLA2 in the presence of NAS was exactly equal to PLA2 activity in the absence of NAS. Only 7% of total radiolabeled products was 2-[1-14C]arachidonoyllysophosphatidylethanolamine after 30 min incubation in the presence or absence of NAS. These data are consistent with a high degree of specificity for the enzyme in using the sn-2 fatty acid of PE.2


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 10.   Dual enzyme activity. The reaction was carried out with 38.5 mM sodium citrate (pH 4.5), DOPC/PE/dicetylphosphate (7/3/1, 128 µM phospholipid) liposomes containing L-alpha -1-acyl-2-[1-14C]arachidonoyl-PE (130,000 cpm), 10 µg/ml BSA, 6 ng/ml purified transacylase in the absence or presence of 10 µM N-acetylsphingosine. The incubation was carried out at 37 °C. The formation of O-acyl-NAS and the release of arachidonic acid in the absence of enzyme was used as a control at each point and subtracted as a blank from the total activity.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Our previous study demonstrated that the transacylase activity of brain is higher than that of other tissues (5). Therefore brain was chosen as a starting material. In a preliminary study, it was confirmed that the transacylase activity is efficiently released by sonication from MDCK cell homogenate prepared in isotonic buffer, consistent with its localization in an intracellular compartment. In the present study, fresh calf brains were frozen once before use. The thawed tissues were homogenized with a hypotonic buffer using a Polytron. This procedure presumably lysed intracellular compartments efficiently and resulted in an increased release of the enzyme. However, a very low recovery (20-30%) of enzyme activity was initially obtained after ammonium sulfate fractionation. Recovery was markedly improved by diluting the dialysate before the 100,000 × g centrifugation. A high protein concentration might have caused a nonspecific coprecipitation of the enzyme with insoluble materials during ultracentrifugation. The observed rebound of enzyme activity after DEAE-Sephacel chromatography might have been due to separation of the enzyme from an endogenous inhibitor.

The concanavalin A-agarose chromatography step was one of the most successful purification steps. The enzyme was tightly bound to concanavalin A-agarose resin and specifically released from the resin with 500 mM alpha -methyl-D-mannopyranoside (Fig. 4). At this stage, a major band of molecular mass about 40 kDa and some minor bands of that between 43 and 60 kDa were observed in the active fractions from the concanavalin A column by SDS-PAGE (Fig. 5). Further purification by the heparin-Sepharose column showed an exact coincidence between the transacylase activity and a stained protein of a molecular mass of about 40 kDa as determined by SDS-PAGE (Fig. 6), consistent with the molecular mass assignment by Sephadex G-75 chromatography (Fig. 3B). These data are consistent with the purified transacylase being a 40-kDa oligomannose-containing glycoprotein with a single polypeptide chain. This enzyme has a pH optimum of 4.5. Although suggestive of a lysosomal origin for the transacylase, the enzyme activity was still observed at pH 5-6.5 (Fig. 6). Thus the enzyme may function outside the acidic environment of lysosomes.

Secreted PLA2s, group I, II, and III, contain 5-8 disulfide bonds essential for the enzyme activity (13, 14). Reducing these disulfide bonds by thiol reagents results in inhibition of the lipase activity. The calf brain transacylase activity was insensitive to DTT when preincubated at pH 7.4 in Tris buffer or when added directly to the assay mixture (Table II). Using a partially purified enzyme (step 7), it was found that the enzyme was tightly bound to organomercurial-agarose resin (Affi-Gel 501; Bio-Rad) and eluted by 200 mM 2-mercaptoethanol (data not shown). This indicates that the enzyme has free thiol group(s) exposed on its molecular surface. Pretreatment of the purified enzyme with NEM had no effect on the enzyme activity (Table II). These results suggest that the free thiol group(s) of the enzyme that is thiol reagent-sensitive is neither functionally important nor found in the catalytic site.

Recently human cPLA2 was found to have a transacylase activity that is CoA-independent, raising the possibility that cPLA2 forms an acyl-enzyme intermediate (15). Site-directed mutagenesis of cPLA2 demonstrated that the serine 228 essential for the catalytic activity of the 85-kDa cPLA2 may be the active site nucleophile. (17). Additionally, it was reported that AACOCF3 is both a slow and tight binding inhibitor of cPLA2 that may form a hemiketal enzyme-inhibitor complex (16, 18). The reaction mechanism of cPLA2 thus might be similar to that of serine protease, esterase, or lipase (15-18). In general, these types of enzymes are also sensitive to PMSF and diisopropylfluoride. In the present study, neither 1 mM PMSF nor 28 µM AACOCF3 significantly inhibited the activity of the purified transacylase (Table II and Fig. 8). The action of these inhibitors on the enzyme in 100,000 × g supernatant from MDCK cells homogenate was also not significant (5). These results suggest that neither the calf brain transacylase nor MDCK cell transacylase has an essential serine residue for the transacylase reaction.

Although the purified transacylase did not require Ca2+ or Mg2+ for activity, these cations enhanced the activity (Table II). In the previous study, it was observed that 1 mM Ca2+ slightly enhanced the transacylase activity in the 100,000 × g supernatant obtained from MDCK cells homogenate (5). It is known that divalent cations affect the physical state of lipid assembly (12). The enhancement of the enzyme activity is thought to be due to formation of ionic bridges by these divalent cations on liposomes, thereby modulating molecular packing and availability of substrate.

Recently, it has been reported that myocardial cytosolic iPLA2 and macrophage cytosolic iPLA2 interact with ATP, acting on the enzyme as an activator or a stabilizer (10, 11). The purified calf brain transacylase was not activated in the presence of ATP (Table II). It has also been reported that BEL is a potent covalently bound inhibitor of these iPLA2s but not other PLA2s (secreted Ca2+-dependent PLA2 or cytosolic Ca2+-dependent PLA2) (19, 20). Myocardial iPLA2 activity was completely abolished by pre-incubation of the iPLA2 with 1 µM BEL (19), and half-maximal inhibition of macrophage iPLA2 activity was observed at 60 nM after a 5 min preincubation (20). Preincubation of the calf brain transacylase with 3 µM BEL had no significant effect on the enzyme activity (Table II). These results suggest that a functional group sensitive to BEL inhibitors does not exist around the active site and/or lipid recognition site of the calf brain transacylase.

Bartolf and Franson (22) reported that a lysosomal iPLA2 from bovine adrenal medulla was stabilized by adding Triton X-100, although the lipase activity was reduced in a dose-dependent manner at higher Triton X-100 concentrations (22). A similar effect was observed on the purified calf brain transacylase, where activity was completely abolished in the presence of more than 773 µM Triton X-100 (Fig. 9). On the contrary, iPLA2 (39 kDa) partially purified from bovine brain has the optimal concentration of Triton X-100 at 773-1546 µM, suggesting that the transacylase is distinct from the 39-kDa iPLA2 (27).

Using iPLA2 (39 kDa) partially purified from bovine brain, Yang et al. (21) reported that heparin at either 100 or 200 µg/ml produced 25% inhibition of the iPLA2 activity. The calf brain transacylase was bound to heparin-Sepharose resin under a low ionic condition and eluted by a low concentration of NaCl consistent with weak ionic binding (Fig. 6). In the present study, 50% inhibition of the transacylase activity occurred at 10-100 µg/ml heparin (Table II). The interaction between the enzyme and heparin might be very weak in the assay system because of the ionic strength. Alternatively, heparin is thought to interact with liposomes and to change the surface properties and the molecular packing of liposomes. As a result, an apparent activity of the enzyme might be partially suppressed.

iPLA2s have been found in many mammalian tissues and cells (23), and some successful purification of iPLA2s has been reported, including canine myocardium (10), P388D1 macrophages (11), and rat lung (24), brain (25), and kidney (26). Some biochemical properties of the calf brain transacylase, including insensitivity to DTT and Ca2+ independence for enzyme activity, are found among iPLA2s. However, many of iPLA2s have a neutral pH optimum. For example, although two kinds of cytosolic iPLA2, 110 kDa and 39 kDa, were partially purified from bovine brain, the optimal pH values of 110-kDa and 39-kDa enzymes were 7.4 and 8.0, respectively (27). The purified rat kidney soluble iPLA2 has a molecular mass of 28 kDa and a neutral pH optimum (26). Although a soluble acidic pH-optimum iPLA2 was purified from rat brain by a protocol similar to ours, the enzyme displayed a molecular mass of 58 kDa and was highly phosphatidic acid-selective (25). Recently Wang et al. (24) purified an acidic-pH optimum iPLA2 from rat lung. This enzyme displayed some properties similar to the calf brain transacylase, including insensitivity to 2-mercaptoethanol, ATP, AACOCF3, and the binding ability to heparin-Sepharose resin. However, the molecular mass of the lung iPLA2 was 15 kDa (24). A soluble, lysosomal iPLA2 partially purified from bovine adrenal medulla showed a basic pI, Triton X-100 inhibition, and binding to concanavalin A-agarose resin (22). These profiles are common to the calf brain transacylase. This enzyme, however, gave a molecular mass of 30.6 kDa.

More recently, a calcium-independent lysosomal PLA2 has been cloned. This enzyme displayed a similar pharmacologic profile to the 15-kDa protein but has a molecular mass of 25.8 kDa (28).

In the previous study, it was strongly suggested that MDCK cell transacylase has dual enzyme activity, i.e. transacylase and PLA2 (5). In the present study, both transacylase and phospholipase A activities were observed in the purified protein. The assay in which DOPC/L-alpha -1-acyl-2-[1-14C]arachidonoyl-PE/dicetylphosphate liposomes was used as an acyl donor demonstrated that the calf brain transacylase possesses dual enzyme functions, viz. transacylase and phospholipase A activities (Fig. 10). The enzyme also produced 2-[14C]arachidonyllyso-PE but only as a small fraction of the total radioactive products. This supports the view that the phospholipase activity of the transacylase has sn-2 fatty acid specificity. These data are consistent with the interpretation that 1-O-acylceramide synthase is a novel Ca2+-independent PLA2.

    ACKNOWLEDGEMENTS

The authors gratefully acknowledge the advice and comments of Norm Radin and Philip Majerus.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants RO1 DK41487 and RO139255 and a Merit Review Research Award from the Veterans Administration (to J. A. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger An Established Investigator of the American Heart Association. To whom correspondence should be addressed: Nephrology Div., Dept. of Internal Medicine, University of Michigan, Box 0676, Rm. 1560 MSRBII, 1150 West Medical Center Dr., Ann Arbor, MI 48109-0676. Tel.: 313-763-0992; Fax: 313-763-0982; E-mail: jshayman{at}umich.edu.

1 The abbreviations used are: NAS, N-acetylsphingosine; AACOCF3, nonadecyltetraenyl trifluoromethyl ketone; BEL, (E)-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one; PLA2, phospholipase A2; cPLA2 and iPLA2, cytosolic and calcium-independent PLA2, respectively; DOPC, dioleoylphosphatidylcholine; DTT, DL-dithiothreitol; MDCK, Madin-Darby canine kidney; NEM, N-ethylmaleimide; PMSF, phenylmethylsulfonyl fluoride; PE, phosphatidylethanolamine; Con A, concanavalin A; PAGE, polyacrylamide gel electrophoresis; BSA, bovine serum albumin.

2 The reaction was carried out for 30 min with purified enzyme and DOPC/L-alpha -1-acyl-2-[1-14C]arachidonoyl-PE/dicetylphosphate liposomes as an acyl donor both in the presence and absence of NAS. In the presence of NAS the product profile in cpm was arachidonic acid 14356, 1-O-acyl-NAS 7050, and sn2-arachidonoyl-PE 1652. The lyso-arachidonoyl-PE represented 7.2% of the reaction products. In the absence of NAS the products were arachidonic acid 21,734 and lyso-arachidonoyl-PE 1657. The lyso-arachidonoyl-PE represented 7.1% of the reaction products.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Hannun, Y. A. (1994) J. Biol. Chem. 269, 3125-3128[Free Full Text]
  2. Kolesnick, R., and Golde, D. W. (1994) Cell 77, 325-328[Medline] [Order article via Infotrieve]
  3. Sheela Rani, C. S., Abe, A., Chang, Y., Rosenzweig, N., Saltiel, A. R., Radin, N. S., and Shayman, J. A. (1995) J. Biol. Chem. 270, 2859-2867[Abstract/Free Full Text]
  4. Abe, A., Radin, S. A., and Shayman, J. A. (1996) Biochim. Biophs. Acta 1299, 333-341[Medline] [Order article via Infotrieve]
  5. Abe, A., Shayman, J. A., and Radin, N. S. (1996) J. Biol. Chem. 271, 14383-14389[Abstract/Free Full Text]
  6. Gaver, R. C., and Sweeley, C. C. (1966) J. Am. Chem. Soc. 88, 3643-3647[Medline] [Order article via Infotrieve]
  7. Reisfeld, R. A., Lewis, U. J., and Williams, D. E. (1962) Nature 195, 281-283
  8. Laemmli, U. K., and Favre, M. (1973) J. Mol. Biol. 80, 575-599[Medline] [Order article via Infotrieve]
  9. Bensadoun, A., and Weinstein, D. (1976) Anal. Biochem. 70, 241-250[Medline] [Order article via Infotrieve]
  10. Hazen, S. L., Stuppy, R. J., and Gross, R. W. (1990) J. Biol. Chem. 265, 10622-10630[Abstract/Free Full Text]
  11. Ackerman, E, J., Kempner, E. S., and Dennis, E. A. (1994) J. Biol. Chem. 269, 9227-9233[Abstract/Free Full Text]
  12. Lichtenberg, D., and Barenholz, Y. (1988) Methods Biochem. Anal. 33, 337-462[Medline] [Order article via Infotrieve]
  13. Dennis, E. A. (1994) J. Biol. Chem. 269, 13057-13060[Free Full Text]
  14. Chen, J., Engle, S. J., Seilhamer, J. J., and Tischfield, J. A. (1994) J. Biol. Chem. 269, 23018-23024[Abstract/Free Full Text]
  15. Reynolds, L. J., Hughes, L. L., Louis, A. I., Kramer, R. M., and Dennis, E. A. (1993) Biochim. Biophs. Acta 1167, 272-280[Medline] [Order article via Infotrieve]
  16. Trimble, L. A., Street, I. P., Perrier, H., Tremblay, N. M., Weech, P. K., and Bernstein, M. A. (1993) Biochemistry 32, 12560-12565[Medline] [Order article via Infotrieve]
  17. Sharp, J. D., Pickard, R. T., Chiou, X. J., Manetta, J. V., Kovasevic, S., Miller, J. R., Varshavsky, A. D., Roberts, E. F., Strifler, B. A., Brems, D. N., and Kramer, R. M. (1994) J. Biol. Chem. 269, 23250-23254[Abstract/Free Full Text]
  18. Street, I. P., Lin, H. K., Laliberte, F., Ghomashchi, F., Wang, Z., Perrier, H., Tremblay, N. M., Huang, Z., Weech, P. K., and Gelb, M. H. (1993) Biochemistry 32, 5935-5940[Medline] [Order article via Infotrieve]
  19. Hazen, S. L., Zupan, L. A., Weiss, R. H., Getman, D. P., and Gross, R. W. (1991) J. Biol. Chem. 266, 7227-7232[Abstract/Free Full Text]
  20. Ackerman, E. J., Conde-Frieboes, K., and Dennis, E. A. (1995) J. Biol. Chem. 270, 445-450[Abstract/Free Full Text]
  21. Yang, H. -C., Farooqui, A. A., and Horrocks, L. A. (1994) Biochem. J. 299, 91-95[Medline] [Order article via Infotrieve]
  22. Bartolf, M., and Franson, R. C. (1990) Biochim. Biophys. Acta 1042, 247-254[Medline] [Order article via Infotrieve]
  23. Balsinde, J., and Dennis, E. A. (1997) J. Biol. Chem. 272, 16069-16072[Free Full Text]
  24. Wang, R., Dodia, C. R., Jain, M. K., and Fisher, A. B. (1994) Biochem. J. 304, 131-137[Medline] [Order article via Infotrieve]
  25. Thomson, F. J., and Clark, M. A. (1995) Biochem. J. 306, 305-309[Medline] [Order article via Infotrieve]
  26. Portilla, D., and Dai, G. (1996) J. Biol. Chem. 271, 15451-15457[Abstract/Free Full Text]
  27. Hirashima, Y., Farooqui, A. A., Mills, J. S., and Horrocks, L. A. (1992) J. Neurochem. 59, 708-714[Medline] [Order article via Infotrieve]
  28. Kim, T-S., Sundaresh, C. S., Feinstein, S. I., Dodia, C., Skach, W. R., Jain, M. K., Seki, N., Ishikawa, K-i., Nomura, N., and Fisher, A. R. (1997) J. Biol. Chem. 272, 2542-2550[Abstract/Free Full Text]
  29. McIlavine, T. C. (1921) J. Biol. Chem. 49, 183-186[Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.